Annexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré Syndrome

Max Gelman

Senior Editor

Annexon Biosciences reported new Phase 3 data for its Guillain-Barré Syndrome (GBS) drug Tuesday morning, saying the low dose achieved the trial’s primary endpoint. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Annexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré Syndrome

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

An­nex­on pro­claims Phase 3 win for com­ple­ment in­hibitor in Guil­lain-Bar­ré Syn­drome

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Annexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré Syndrome